Markets/ForexArticle

Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1

Finance Review Daily is tracking this developing story; finance review daily will provide updates as verified details become available.

SL

Sophie Laurent · FX & Rates Desk · 15 Sept 2026 · 04:20 · 1 min read

Share

Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1.

Euro / US Dollar

EURUSD

Full profile →

1.1537▼ 0.12%

As of 14/09/2026, 21:00:00

Finance Review Daily is tracking this development following a report from the original source. Further verified details were not immediately available.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.

Share this story

SL

Written by

Sophie Laurent

FX & Rates Desk

Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.

Market Snapshot

Delayed

EUR/USD1.1537▼ 0.12%GBP/USD1.3486▼ 0.11%USD/CHF0.8182▲ 0.09%BTC/USD77,654.76▼ 0.68%ETH/USD2,491.45▼ 0.97%XAU/USD4,303.77▲ 0.13%

Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1

Euro / US Dollar

Market Snapshot

Related Reading

Asian Currencies Climb as Yen Holds Near Seven-Month High, Dollar Falters

Trump approval rises from record low as Democrats widen lead

Solana transactions just got more than 3 times bigger, giving an edge over Ethereum

Canada Seeks C$1 Trillion in Foreign Investment as US Tariff Threat Looms

Swiss Poll Finds 87% Support Social Media Ban for Youths